The role of gut microbiota in the pharmacokinetics of antihypertensive drugs
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Min Sun | - |
dc.contributor.author | Yu, Jun Sang | - |
dc.contributor.author | Yoo, Hye Hyun | - |
dc.contributor.author | Kim, Dong-Hyun | - |
dc.date.accessioned | 2021-06-22T12:02:50Z | - |
dc.date.available | 2021-06-22T12:02:50Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2018-04 | - |
dc.identifier.issn | 1043-6618 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/6373 | - |
dc.description.abstract | The intestine is one of the most important sites for the metabolism of several xenobiotic compounds. In addition to intestinal drug-metabolizing enzymes and drug transporters, gut microbial enzymes modulate the biotransformation of orally administered drugs in the gastrointestinal tract. Antihypertensive drugs such as amlodipine and nifedipine could be metabolized by gut microbial enzymes, which may influence drug absorption, leading to changes in pharmacological potency of the drug and eventual failure of the appropriate blood pressure control or unexpected side effects. This may suggest that there are additional mechanisms that can alter the therapeutic efficacy of antihypertensive drugs, especially in certain pathological conditions of the gastrointestinal tract or with concomitant use of substances such as antibiotics and probiotics that might alter the gut microbial composition. This review describes the metabolism of antihypertensive drugs by hepatic and intestinal microbial enzymes in an attempt to understand the potential effects of gut microbiota on their pharmacokinetics. (C) 2018 Elsevier Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Academic Press | - |
dc.title | The role of gut microbiota in the pharmacokinetics of antihypertensive drugs | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoo, Hye Hyun | - |
dc.identifier.doi | 10.1016/j.phrs.2018.01.019 | - |
dc.identifier.scopusid | 2-s2.0-85043506844 | - |
dc.identifier.wosid | 000433016900016 | - |
dc.identifier.bibliographicCitation | Pharmacological Research, v.130, pp.164 - 171 | - |
dc.relation.isPartOf | Pharmacological Research | - |
dc.citation.title | Pharmacological Research | - |
dc.citation.volume | 130 | - |
dc.citation.startPage | 164 | - |
dc.citation.endPage | 171 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | HUMAN INTESTINAL BACTERIA | - |
dc.subject.keywordPlus | BETA-GLUCURONIDASE ACTIVITY | - |
dc.subject.keywordPlus | RAT CECAL CONTENTS | - |
dc.subject.keywordPlus | 5-AMINOSALICYLIC ACID | - |
dc.subject.keywordPlus | P-GLYCOPROTEIN | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | MULTIDRUG TRANSPORTER | - |
dc.subject.keywordPlus | BIOLOGICAL-ACTIVITIES | - |
dc.subject.keywordPlus | GNOTOBIOTIC-RATS | - |
dc.subject.keywordPlus | EPITHELIAL-CELLS | - |
dc.subject.keywordAuthor | Gut microbiota | - |
dc.subject.keywordAuthor | Antihypertensive | - |
dc.subject.keywordAuthor | Metabolism | - |
dc.subject.keywordAuthor | Pharmacokinetics | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1043661817310666?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.